Effects of IL-6, JAK, TNF inhibitors, and CTLA4-Ig on knee symptoms in patients with rheumatoid arthritis

Effects of IL-6, JAK, TNF inhibitors, and CTLA4-Ig on knee symptoms in patients with rheumatoid arthritis

Abstract This study aims to identify factors influencing the alleviation of knee joint symptoms in patients with rheumatoid arthritis treated with biologic or target synthetic disease-modifying antirheumatic drugs (b/tsDMARDs). Among 2321 patients who started b/tsDMARDs between 2010 and 2023, we foc...

Full description

Saved in:

Bibliographic Details
Main Authors:	Koichi Murata, Ryuji Uozumi, Takayuki Fujii, Akira Onishi, Kosaku Murakami, Hideo Onizawa, Masao Tanaka, Akio Morinobu, Shuichi Matsuda
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-07-01
Series:	Scientific Reports
Subjects:	Rheumatoid arthritis Knee arthritis Disease-modifying antirheumatic drugs CTLA4-Ig IL-6
Online Access:	https://doi.org/10.1038/s41598-024-66064-3
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Author Correction: Effects of IL-6, JAK, TNF inhibitors, and CTLA4-Ig on knee symptoms in patients with rheumatoid arthritis
by: Koichi Murata, et al.
Published: (2024-12-01)

Impact of COVID-19 on gene Expression of CTLA-4 and Its Potential Role in the Development of Rheumatoid Arthritis: A Post-Infection Analysis.
by: Maryam Sanguor, et al.
Published: (2025-06-01)

EVALUATION OF THE CONTENT OF CD4+CD25+CD127LOW REGULATORY T CELLS AND THEIR FUNCTIONAL STATUS ACCORDING TO THE EXPRESSION OF CTLA-4 AND CD39 MOLECULES IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: G. A. Zhulai, et al.
Published: (2014-06-01)

Therapeutic effects of CTLA4Ig-overexpressing mesenchymal stem cell-derived extracellular vesicles in a mouse model of rheumatoid arthritis
by: Eun Wha Choi, et al.
Published: (2025-07-01)

Comparison of the Efficacy and Safety of Disease‐Modifying Antirheumatic Drugs Combination Therapies: A Systematic Review and Network Meta‐Analysis
by: Linfeng Liu, et al.
Published: (2025-03-01)

Difficult-to-treat rheumatoid arthritis in the clinical practice of a rheumatological hospital. First look
by: A. V. Gordeev, et al.
Published: (2022-05-01)

Immune checkpoint inhibitor-induced myocarditis and multiple adverse events with pre-existing rheumatoid arthritis: a case report and literature review
by: Shion Kachi, et al.
Published: (2025-08-01)

Conventional synthetic disease-modifying antirheumatic drug use by race/ethnicity and factors associated with initiating biologics in Malaysian patients with rheumatoid arthritis
by: Suad Mohammed, et al.
Published: (2019-01-01)

Persistence of biological agents over an eight-year period in rheumatoid arthritis and spondyloarthritis patients
by: María Ángeles González-Fernández, et al.
Published: (2019-01-01)

INFLIXIMAB IN TREATMENT OF ACTIVE JUVENILE ARTHRITIS
by: E. S. Zholobova, et al.
Published: (2012-05-01)

MODERN VIEWS ON PATHOGENETIC THERAPY OF RHEUMATOID ARTHRITIS
by: D. G. Rekalov, et al.
Published: (2013-12-01)

End-stage rheumatoid arthritis: specific features of patient management
by: Nadezhda Aleksandrovna Shostak, et al.
Published: (2013-06-01)

Experience of guselkumab usage in the treatment of patients with psoriatic arthritis in real clinical practice
by: E. Yu. Loginova, et al.
Published: (2021-10-01)

Early rheumatoid arthritis therapy: comparative characteristic of delagil, sulphasalazine and methotrexate
by: T S Salnikova, et al.
Published: (2003-08-01)

A Response to: Letter to the Editor Regarding “Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance”
by: Bogdan Batko, et al.
Published: (2025-01-01)

The tumor necrosis factor-α inhibitor golimumab in the treatment of rheumatoid arthritis
by: Natalia Vladimirovna Chichasova
Published: (2014-12-01)

The Effects of Disease-Modifying Antirheumatic Drugs on Cardiovascular Risk in Inflammatory Joint Diseases: Current Evidence and Uncertainties
by: Garmish O, et al.
Published: (2025-08-01)

Targeted Therapy for Rheumatoid Arthritis in the New Era
by: WANG Jun, et al.
Published: (2025-01-01)

Advances in the Drugs Treatment of Psoriatic Arthritis
by: LU Chaofan, et al.
Published: (2024-12-01)

STRATEGY FOR DOSE REDUCTION AND DISCONTINUATION OF BIOLOGICAL AGENTS IN RHEUMATOID ARTHRITIS REMISSION
by: M. A. Kotovskaya, et al.
Published: (2018-03-01)

The problem of laboratory monitoring in therapy with disease-modifying antirheumatic drugs and biological agents in patients with rheumatoid arthritis
by: Yu. V. Muravyev, et al.
Published: (2018-09-01)

Rheumatoid arthritis: problems of treatment at the present stage
by: N. V. Chichasova
Published: (2018-12-01)

Antirheumatic Medication Calendar Significantly Improves Adherence in First-Time Methotrexate Users: A Prospective, Single-Blind, Randomized Controlled Trial
by: Yuan F, et al.
Published: (2025-07-01)

Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance
by: Bogdan Batko, et al.
Published: (2024-07-01)

Peculiarities of pharmacotherapy of patients with rheumatoid arthritis associated with interstitial lung disease
by: A. V. Gordeev, et al.
Published: (2024-02-01)

Pharmacoeconomic study of active psoriatic arthritis treatment
by: A. V. Rudakova, et al.
Published: (2025-02-01)

Impact of Adherence to Golimumab on Disease Flares in Rheumatoid Arthritis: Results from a Canadian Observational Study
by: Bessette L, et al.
Published: (2025-06-01)

LONG-TERM SAFETY AND EFFICACY OF TOCILIZUMAB IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS OF MODERATE OR HIGH ACTIVITY (RESULTS OF PHASE III MULTICENTER EXTENSION CLINICAL STUDY ML28124)
by: E. L. Nasonov, et al.
Published: (2018-07-01)

Course and outcomes of COVID-19 in patients with immunoinflammatory rheumatic diseases: Preliminary data from the NIIR/APP-COVID-19 registry and literature review
by: E. L. Nasonov, et al.
Published: (2021-12-01)

Body composition and skeletal muscles status in patients with rheumatoid arthritis during treatment with biologic disease-modifying antirheumatic drugs
by: O. V. Dobrovolskaya, et al.
Published: (2025-02-01)

The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patients
by: A. E. Karateev, et al.
Published: (2022-05-01)

Beliefs, preferences, and informational needs of patients with rheumatoid arthritis and concomitant cancer: a qualitative study
by: Juan I. Ruiz, et al.
Published: (2025-07-01)

Real-World Safety and Efficacy of Targeted Therapies in Rheumatoid Arthritis: A 5-Year, 5130-Case Follow-Up from FIRST Registry
by: Koshiro Sonomoto, et al.
Published: (2025-04-01)

Treatment of systemic juvenile idiopathic arthritis: conventional treatment versus biologics
by: Seher Şener, et al.
Published: (2025-02-01)

Enthesitis is a clue to the diagnosis of spondyloarthritis, focus on psoriatic arthritis
by: Ye. D. Yehudina, et al.
Published: (2021-02-01)

Achievement of minimal disease activity in psoriatic arthritis according to the time of administration of synthetic disease-modifying antirheumatic drugs, a comparative analysis of the efficacy of oral and subcutaneous methotrexate. Data from the All-Russian Psoriatic Arthritis Registry
by: T. V. Korotaeva, et al.
Published: (2021-02-01)

Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region
by: Zoltán Kaló, et al.
Published: (2017-01-01)

CTLA-4 expression on tregs is needed for suppression of autoimmune uveitis
by: Minjun Ahn, et al.
Published: (2025-05-01)

Występowanie polimorfizmu w pozycji 49 eksonie 1 genu CTLA-4 u dzieci z chorobą Hashimoto
by: Anna M. Kucharska, et al.
Published: (2006-09-01)

GOLIMUMAB — A NEW TNF α-BLOCKER. THE REVIEW OF THE EFFICACY AND SAFETY EVALUATION RESULTS
by: R. V. Denisova, et al.
Published: (2012-07-01)